Sonstiges: |
- Nachgewiesen in: MEDLINE
- Sprachen: English
- Publication Type: Journal Article; Review
- Language: English
- [Inflammopharmacology] 2024 Jun; Vol. 32 (3), pp. 1777-1789. <i>Date of Electronic Publication: </i>2024 Apr 06.
- MeSH Terms: Dermatitis, Atopic* / therapy ; Dermatitis, Atopic* / drug therapy ; Dermatitis, Atopic* / immunology ; Immunotherapy* / methods ; Humans ; Animals ; Quality of Life ; Immunosuppressive Agents / therapeutic use ; Immunologic Factors / therapeutic use ; Immunologic Factors / pharmacology
- References: Bauman JN, Doran AC, King-Ahmad A, Sharma R, Walker GS, Lin J et al (2022) The pharmacokinetics, metabolism, and clearance mechanisms of abrocitinib, a selective Janus kinase inhibitor, in humans. Drug Metab Dispos 50:1106–1118. (PMID: 3570118210.1124/dmd.122.000829) ; Beck LA, Thaçi D, Deleuran M, Blauvelt A, Bissonnette R, de Bruin-Weller M et al (2020) Dupilumab provides favorable safety and sustained efficacy for up to 3 years in an open-label study of adults with moderate-to-severe atopic dermatitis. Am J Clin Dermatol 21:567–577. (PMID: 32557382737164710.1007/s40257-020-00527-x) ; Bissonnette R, Pavel AB, Diaz A, Werth JL, Zang C, Vranic I et al (2019) Crisaborole and atopic dermatitis skin biomarkers: an intrapatient randomized trial. J Allergy Clin Immunol 144:1274–1289. (PMID: 3141954410.1016/j.jaci.2019.06.047) ; Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D et al (2017) Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet 389:2287–2303. (PMID: 2847897210.1016/S0140-6736(17)31191-1) ; Blauvelt A, Langley RG, Lacour JP, Toth D, Laquer V, Beissert S et al (2022) Long-term 2 year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: interim analysis of the ECZTEND open-label extension trial. J Am Acad Dermatol 87:815–824. (PMID: 3586346710.1016/j.jaad.2022.07.019) ; Chang EH, Carnevale D, Chavan SS (2023) Editorial: understanding and targeting neuro-immune interactions within disease and inflammation. Front Immunol 18(14):1201669. https://doi.org/10.3389/fimmu.2023.1201669. (PMID: 10.3389/fimmu.2023.1201669) ; Chen Q, Cui L, Hu Y, Chen Z, Gao Y, Shi Y (2023) Short-term efficacy and safety of biologics and Janus kinase inhibitors for patients with atopic dermatitis: a systematic review and meta-analysis. Heliyon 9(11):e22014. https://doi.org/10.1016/j.heliyon.2023.e22014. (PMID: 10.1016/j.heliyon.2023.e220143803479810685203) ; Colletti A, Pellizzato M, Cicero AF (2023) The possible role of probiotic supplementation in inflammation: a narrative review. Microorganisms 11(9):2160. https://doi.org/10.3390/microorganisms11092160. (PMID: 10.3390/microorganisms110921603776400410535592) ; Cork MJ, Thaçi D, Eichenfield LF, Arkwright PD, Sun X, Chen Z, Akinlade B et al (2021) Dupilumab provides favourable long-term safety and efficacy in children aged ≥6 to <12 years with uncontrolled severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study. Br J Dermatol 184:857–870. (PMID: 3296948910.1111/bjd.19460) ; Czarnowicki T, He H, Krueger JG, Guttman-Yassky E (2019) Atopic dermatitis endotypes and implications for targeted therapeutics. J Allergy Clin Immunol 143:1–11. (PMID: 3061266310.1016/j.jaci.2018.10.032) ; de Bruin-Weller M, Thaçi D, Smith CH, Reich K, Cork MJ, Radin A, Zhang Q et al (2018) Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ). Br J Dermatol 178:1083–1101. (PMID: 2919301610.1111/bjd.16156) ; Drakos A, Torres T, Vender R (2024) Emerging oral therapies for the treatment of psoriasis: a review of pipeline agents. Pharmaceutics 16(1):111. https://doi.org/10.3390/pharmaceutics16010111. (PMID: 10.3390/pharmaceutics160101113825812110819460) ; Duhen R, Ballesteros-Merino C, Frye AK, Tran E, Shu-Ching Chang T, Koguchi Y et al (2021) Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells. Nat Commun 12:1047. (PMID: 33594075788690910.1038/s41467-021-21383-1) ; Ferrara F, Vitiello A (2021) Scientific Hypothesis for treatment of COVID-19’s lung lesions by adjusting ACE/ACE2 Imbalance. Cardiovasc Toxicol 21(6):498–503. https://doi.org/10.1007/s12012-021-09649-y. (PMID: 10.1007/s12012-021-09649-y338353868032553) ; Furue K, Ito T, Tsuji G, Ulzii D, Vu YH, Kido-Nakahara M et al (2019) The IL-13-OVOL1-FLG axis in atopic dermatitis. Immunology 158:281–286. (PMID: 31509236685693010.1111/imm.13120) ; Gooderham MJ, Forman SB, Bissonnette R, Beebe JS, Zhang W, Banfeld C et al (2019) Efficacy and safety of oral janus kinase 1 inhibitor abrocitinib for patients with atopic dermatitis: a phase 2 randomized clinical trial. JAMA Dermatol 155:1371–1379. (PMID: 31577341677722610.1001/jamadermatol.2019.2855) ; Gutermuth J, Pink AE, Worm M, Soldbro L, Bjerregård Øland C, Weidinger S et al (2022) Tralokinumab plus topical corticosteroids in adults with severe atopic dermatitis and inadequate response to or intolerance of ciclosporin A: a placebo-controlled, randomized, phase III clinical trial (ECZTRA 7). Br J Dermatol 186:440–452. (PMID: 3469837110.1111/bjd.20832) ; Guttman-Yassky E, Pavel AB, Zhou L, Estrada YD, Zhang N, Xu H et al (2019a) GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis. J Allergy Clin Immunol 144:482-93e7. (PMID: 3073817110.1016/j.jaci.2018.11.053) ; Guttman-Yassky E, Silverberg JI, Nemoto O, Forman SB, Wilke A, Prescilla R et al (2019b) Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study. J Am Acad Dermatol 80:913-21e9. (PMID: 2941001410.1016/j.jaad.2018.01.018) ; Guttman-Yassky E, Blauvelt A, Eichenfeld LF, Paller AS, Armstrong AW, Drew J et al (2020a) Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis: a phase 2b Randomized Clinical Trial. JAMA Dermatol 156:411–420. (PMID: 32101256714238010.1001/jamadermatol.2020.0079) ; Guttman-Yassky E, Thaçi D, Pangan AL, Hong HC, Paap KA, Reich A et al (2020b) Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. J Allergy Clin Immunol 2020(145):877–884. (PMID: 10.1016/j.jaci.2019.11.025) ; Harb H, Chatila TA (2019) Mechanisms of dupilumab. Clin Exp Allergy 50:5–14. (PMID: 31505066693096710.1111/cea.13491) ; Kwon S (2022) Molecular dissection of Janus kinases as drug targets for inflammatory diseases. Front Immunol 8(13):1075192. https://doi.org/10.3389/fimmu.2022.1075192. (PMID: 10.3389/fimmu.2022.1075192) ; Licata G, Gambardella A, Tancredi V, Calabrese G, De Rosa A, Alfano R et al (2022) Face atopic dermatitis resistant to dupilumab: a case series of three patients successfully treated with upadacitinib. J Eur Acad Dermatol Venereol 36:e150–e152. (PMID: 3455380010.1111/jdv.17705) ; Mazzoleni L, Borsino C, Zovi A (2022) Study of overall survival associated with nintedanib and pirfenidone in patients with idiopathic pulmonary fibrosis: a real-life comparison. Eur J Hosp Pharm. https://doi.org/10.1136/ejhpharm-2021-003202. (PMID: 10.1136/ejhpharm-2021-003202350640209986917) ; Mogul A, Corsi K, McAuliffe L (2019) Baricitinib: the second FDA-approved JAK inhibitor for the treatment of rheumatoid arthritis. Ann Pharmacother 53:947–953. (PMID: 3090711610.1177/1060028019839650) ; Nemoto O, Furue M, Nakagawa H, Shiramoto M, Hanada R, Matsuki S et al (2016) The first trial of CIM331, a humanized antihuman interleukin-31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double-blind, placebo- controlled study. Br J Dermatol 174:296–304. (PMID: 2640917210.1111/bjd.14207) ; Newsom M, Bashyam AM, Balogh EA, Feldman SR, Strowd LC (2020) New and emerging systemic treatments for atopic dermatitis. Drugs 80:1041–1052. (PMID: 32519223728168910.1007/s40265-020-01335-7) ; Paller AS, Wollenberg A, Siegfried E, Thaçi D, Cork MJ, Arkwright PD et al (2021) Laboratory Safety of dupilumab in patients aged 6–11 years with severe atopic dermatitis: results from a phase iii clinical trial. Paediatr Drugs 23:515–527. (PMID: 34462864841859110.1007/s40272-021-00459-x) ; Parmentier JM, Voss J, Graff C, Schwartz A, Argiriadi M, Freidman M et al (2018) In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494). BMC Rheumatol 2:23. (PMID: 30886973639058310.1186/s41927-018-0031-x) ; Patruno C, Fabbrocini G, Longo G, Argenziano G, Ferrucci SM, Stingeni L et al (2021a) Effectiveness and safety of long-term dupilumab treatment in elderly patients with atopic dermatitis: a multicenter real-life observational study. Am J Clin Dermatol 22:581–586. (PMID: 3372533710.1007/s40257-021-00597-5) ; Patruno C, Napolitano M, Argenziano G, Peris K, Ortoncelli M, Girolomoni G et al (2021b) DADE-Dupilumab for Atopic Dermatitis of the Elderly study group. Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study. J Eur Acad Dermatol Venereol 35:958–964. (PMID: 3333269710.1111/jdv.17094) ; Pfizer announces positive top-line results from phase 3 study of investigational oral Jak1 candidate, abrocitinib (Pf-04965842), in patients aged 12 and older with moderate to severe atopic dermatitis (2019) Disponibile on line su: ultimo access [10 november 2022]. https://www.pfizer.com/news/press-release/press-release-detail/pfizer_announces_positive_top_line_results_from_phase_3_study_of_investigational_oral_jak1_candidate_abrocitinib_pf_04965842_in_patients_aged_12_and_older_with_moderate_to_severe_atopic_dermatitis. ; Reich K, Teixeira HD, de Bruin-Weller M, Bieber T, Soong W, Kabashima K et al (2021) Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 397:2169–2181. (PMID: 3402300910.1016/S0140-6736(21)00589-4) ; Ruzicka T, Hanifn JM, Furue M, Pulka G, Mlynarczyk I, Wollenberg A, XCIMAStudyGroup et al (2017) Anti-interleukin-31 receptor A antibody for atopic dermatitis. N Engl J Med 376:826–835. (PMID: 2824915010.1056/NEJMoa1606490) ; Seegräber M, Srour J, Walter A, Knop M, Wollenberg A (2018) Dupilumab for treatment of atopic dermatitis. Expert Rev Clin Pharmacol 11:467–474. (PMID: 2955724610.1080/17512433.2018.1449642) ; Silverberg JI, Kantor R (2017) The role of interleukins 4 and/or 13 in the pathophysiology and treatment of atopic dermatitis. Dermatol Clin 35:327–334. (PMID: 2857780210.1016/j.det.2017.02.005) ; Silverberg JI, Pinter A, Pulka G, Poulin Y, Bouaziz JD, Wollenberg A et al (2019) Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus. J Allergy Clin Immunol 145:173–182. (PMID: 3144991410.1016/j.jaci.2019.08.013) ; Silverberg JI, Toth D, Bieber T, Alexis AF, Elewski BE, Pink AE, ECZTRA3studyinvestigators et al (2021) Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial. Br J Dermatol 184:450–463. (PMID: 33000503798618310.1111/bjd.19573) ; Silverberg JI, Rubini NPM, Pires MC, Rossi AB, Zhang A, Chen Z et al (2022) Dupilumab treatment reduces hospitalizations in adults with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol Pract 10:1279–85.e1. (PMID: 3503269510.1016/j.jaip.2021.11.034) ; Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, SOLO1andSOLO2Investigators et al (2016) Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med 375:2335–2348. (PMID: 2769074110.1056/NEJMoa1610020) ; Simpson EL, Flohr C, Eichenfield LF, Bieber T, Sofen H, Taieb A et al (2018) Efficacy and safety of lebrikizumab (an antiIL-13 monoclonal antibody) in adults with moderate- to-severe atopic dermatitis inadequately controlled by topical corticosteroids: a randomized, placebo-controlled phase II trial (TREBLE). J Am Acad Dermatol 78:863-71e11. (PMID: 2935302610.1016/j.jaad.2018.01.017) ; Simpson EL, Paller AS, Siegfried EC, Boguniewicz M, Sher L, Gooderham MJ et al (2020) Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial. JAMA Dermatol 156:44–56. (PMID: 3169307710.1001/jamadermatol.2019.3336) ; Simpson EL, Papp KA, Blauvelt A, Chu CY, Hong HC, Katoh N et al (2022) Efficacy and safety of upadacitinib in patients with moderate to severe atopic dermatitis: analysis of follow-up data from the measure up 1 and measure up 2 randomized clinical trials. JAMA Dermatol 158:404–413. (PMID: 35262646890822610.1001/jamadermatol.2022.0029) ; Stec A, Sikora M, Maciejewska M, Paralusz-Stec K, Michalska M, Sikorska E et al (2023) Bacterial metabolites: a link between gut microbiota and dermatological diseases. Int J Mol Sci 24(4):3494. https://doi.org/10.3390/ijms24043494. (PMID: 10.3390/ijms24043494368349049961773) ; Suarez-Farinas M, Ungar B, da Rosa CJ, Ewald DA, Rozenblit M, Gonzalez J et al (2015) RNA sequencing atopic dermatitis transcriptome profling provides insights into novel disease mechanisms with potential therapeutic implications. J Allergy Clin Immunol 135:1218–1227. (PMID: 2584072210.1016/j.jaci.2015.03.003) ; Uchida H, Kamata M, Mizukawa I, Watanabe A, Agematsu A, Nagata M et al (2019) Real- world efectiveness and safety of dupilumab for the treatment of atopic dermatitis in Japanese patients: a single-centre retrospective study. Br J Dermatol 181:1083–1085. (PMID: 3112786010.1111/bjd.18163) ; Vitiello A, Ferrara F (2022) Association and pharmacological synergism of the triple drug therapy baricitinib/remdesivir/rhACE2 for the management of COVID-19 infection. Naunyn Schmiedebergs Arch Pharmacol 395(1):99–104. https://doi.org/10.1007/s00210-021-02169-0. (PMID: 10.1007/s00210-021-02169-034669002) ; Vitiello A, Ferrara F, Lasala R, Zovi A (2022) Precision medicine in the treatment of locally advanced or metastatic urothelial cancer: new molecular targets and pharmacological therapies. Cancers (Basel) 14(20):5167. https://doi.org/10.3390/cancers14205167. (PMID: 10.3390/cancers1420516736291950) ; Wang C, Kraus CN, Patel KG, Ganesan AK, Grando SA (2020) Realworld experience of dupilumab treatment for atopic dermatitis in adults: a retrospective analysis of patients records. Int J Dermatol 59:253–256. (PMID: 3128649910.1111/ijd.14573) ; Wollenberg A, Howell MD, Guttman-Yassky E, Silverberg JI, Kell C, Ranade K et al (2019) Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb. J Allergy Clin Immunol 143:135–141. (PMID: 2990652510.1016/j.jaci.2018.05.029) ; Wollenberg A, Blauvelt A, Guttman-Yassky E, Worm M, Lynde C, ECZTRA 1 and ECZTRA 2 study investigators et al (2021) Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol 184:437–449. (PMID: 3300046510.1111/bjd.19574) ; Worm M, Simpson EL, Thaçi D, Bissonnette R, Lacour JP, Beissert S et al (2020) Efficacy and safety of multiple dupilumab dose regimens after initial successful treatment in patients with atopic dermatitis: a randomized clinical trial. JAMA Dermatol 156:131–143. (PMID: 3187690010.1001/jamadermatol.2019.3617) ; Xue C, Yao Q, Gu X, Shi Q, Yuan X, Chu Q et al (2023) Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer. Signal Transduct Target Ther 8(1):204. https://doi.org/10.1038/s41392-023-01468-7. (PMID: 10.1038/s41392-023-01468-73720833510196327)
- Contributed Indexing: Keywords: Atopic dermatitis; Immunomodulators; Immunotherapy; Interleukin inhibitors; JAK inhibitors
- Substance Nomenclature: 0 (Immunosuppressive Agents) ; 0 (Immunologic Factors)
- Entry Date(s): Date Created: 20240406 Date Completed: 20240529 Latest Revision: 20240530
- Update Code: 20240531
|